Compugen Ltd. to Present Pooled Analysis of COM701 Phase 1 Trials in Platinum Resistant Ovarian Cancer at ESMO 2025

Reuters2025-07-28

Compugen Ltd. to Present Pooled Analysis of COM701 Phase 1 Trials in Platinum Resistant Ovarian Cancer at ESMO 2025

Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced its plans to present a pooled analysis of data from three Phase 1 trials evaluating COM701 in platinum-resistant ovarian cancer. The analysis will include data on COM701 as both a monotherapy and in combination therapies in heavily pretreated patients. This presentation is scheduled to take place at the European Society for Medical Oncology (ESMO) 2025 conference in Berlin, Germany, from October 17-21, 2025. Dr. Oladapo Yeku from Massachusetts General Hospital is set to deliver the presentation on October 18, 2025. The poster detailing the study will be made available on Compugen's website for further review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN38472) on July 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2554753577?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-28 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554753577","market":"fut","top_or_hot":-1,"title":"Compugen Ltd. to Present Pooled Analysis of COM701 Phase 1 Trials in Platinum Resistant Ovarian Cancer at ESMO 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Compugen Ltd. to Present Pooled Analysis of COM701 Phase 1 Trials in Platinum Resistant Ovarian Cancer at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced its plans to present a pooled analysis of data from three Phase 1 trials evaluating COM701 in platinum-resistant ovarian cancer. The analysis will include data on COM701 as both a monotherapy and in combination therapies in heavily pretreated patients. This presentation is scheduled to take place at the European Society for Medical Oncology (ESMO) 2025 conference in Berlin, Germany, from October 17-21, 2025. Dr. Oladapo Yeku from Massachusetts General Hospital is set to deliver the presentation on October 18, 2025. The poster detailing the study will be made available on Compugen's website for further review.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN38472) on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Compugen Ltd. to Present Pooled Analysis of COM701 Phase 1 Trials in Platinum Resistant Ovarian Cancer at ESMO 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCompugen Ltd. to Present Pooled Analysis of COM701 Phase 1 Trials in Platinum Resistant Ovarian Cancer at ESMO 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-28 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Compugen Ltd. to Present Pooled Analysis of COM701 Phase 1 Trials in Platinum Resistant Ovarian Cancer at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced its plans to present a pooled analysis of data from three Phase 1 trials evaluating COM701 in platinum-resistant ovarian cancer. The analysis will include data on COM701 as both a monotherapy and in combination therapies in heavily pretreated patients. This presentation is scheduled to take place at the European Society for Medical Oncology (ESMO) 2025 conference in Berlin, Germany, from October 17-21, 2025. Dr. Oladapo Yeku from Massachusetts General Hospital is set to deliver the presentation on October 18, 2025. The poster detailing the study will be made available on Compugen's website for further review.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN38472) on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDLQMt2g:1","article_id":"2554753577","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554753577","pubTimestamp":1753700509,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced its plans to present a pooled analysis of data from three Phase 1 trials evaluating COM701 in platinum-resistant ovarian cancer. The analysis will include data on COM701 as both a monotherapy and in combination therapies in heavily pretreated patients. This presentation is scheduled to take place at the European Society for Medical Oncology  2025 conference in Berlin, Germany, from October 17-21, 2025. Dr. Oladapo Yeku from Massachusetts General Hospital is set to deliver the presentation on October 18, 2025. The poster detailing the study will be made available on Compugen's website for further review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Lt","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CGEN":"Compugen医疗","BK4121":"生命科学工具和服务"},"translate_title":"Compugen Ltd.将在ESMO 2025上展示COM701治疗铂类耐药卵巢癌1期试验的汇总分析","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CGEN":0.9},"content_text":"Compugen Ltd. to Present Pooled Analysis of COM701 Phase 1 Trials in Platinum Resistant Ovarian Cancer at ESMO 2025\n    \n\n        Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced its plans to present a pooled analysis of data from three Phase 1 trials evaluating COM701 in platinum-resistant ovarian cancer. The analysis will include data on COM701 as both a monotherapy and in combination therapies in heavily pretreated patients. This presentation is scheduled to take place at the European Society for Medical Oncology (ESMO) 2025 conference in Berlin, Germany, from October 17-21, 2025. Dr. Oladapo Yeku from Massachusetts General Hospital is set to deliver the presentation on October 18, 2025. The poster detailing the study will be made available on Compugen's website for further review.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN38472) on July 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2554753577","isCrawlerRequest":true}